Dusseldorf - Delayed Quote EUR

Avenue Therapeutics Inc (49Y0.DU)

6.27

+6.19

(+101.37%)

At close: April 25 at 8:12 AM GMT+2

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 689,680 shares of the Company’s common stock. The exercised warrants are comprised of warrants to purchase sh

GlobeNewswire 20 days ago

FBIO

FBIOP

ATXI
Avenue Therapeutics Announces Reverse Stock Split

MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will effect a 1-for-75 reverse split of its issued and outstanding common stock. Avenue expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on Apr

GlobeNewswire 25 days ago

ATXI

FBIO

FBIOP
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader (“KOL”) event highlighting expert perspectives on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event wi

GlobeNewswire last month

ATXI

FBIO

FBIOP
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical data at American Epilepsy Society (AES) and American Society for Experimental Neurotherapeutics (ASENT) Annual Meetings and in publication Drug Development Research - - Final agreement reached with FDA on study design and analysis approach for Phase 3 safety study of IV tramadol – MIAMI, March 18, 2024 (G

GlobeNewswire last month

ATXI

FBIO

FBIOP
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that by decision dated March 11, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.

GlobeNewswire 2 months ago

FBIO

FBIOP

ATXI
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of response in humans MIAMI, March 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappe

GlobeNewswire 2 months ago

FBIO

FBIOP

ATXI
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

-In vivo data supports BAER-101’s unique ability to significantly suppress seizures using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy-MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of preclinical in vivo data in

GlobeNewswire 2 months ago

FBIO

FBIOP

ATXI
Sidoti Events, LLC's Virtual January Micro-Cap Conference

NEW YORK, NY / ACCESSWIRE / January 16, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January ...

ACCESSWIRE 3 months ago

CVEO

LLKKF

BTM
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer, will present a corporate update at the Sidoti January Micro-Cap Investor Conference on Thursday, January 18, 2024 at 10:00 a.m. EST. A webcast and subsequent archived replay of th

GlobeNewswire 4 months ago

ATXI

FBIO

FBIOP
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds

MIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into warrant exercise agreements with existing accredited investors for the immediate exercise of certain outstanding warrants to purchase an aggregate of 16.5 million shares of the Company’s common stock. These warrants for

GlobeNewswire 4 months ago

ATXI

FBIO

FBIOP
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol

MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it has reached final agreement with the U.S. Food and Drug Administration (“FDA”) on the Phase 3 safety study protocol and statistical analysis approach, including the primary endpoint, for intravenous (IV) tramadol, which is in

GlobeNewswire 4 months ago

ATXI

FBIO

FBIOP
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

- Topline data remains on track for second quarter of 2024 - MIAMI, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that all patients have been enrolled in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy's Dis

GlobeNewswire 4 months ago

ATXI

FBIO

FBIOP
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting

MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN, will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy at the American Epilepsy Society (AE

GlobeNewswire 5 months ago

FBIO

FBIOP

ATXI
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

- Phase 1b/2a clinical trial of AJ201 remains on track to report topline data in second quarter of 2024 - - Positive BAER-101 preclinical data accepted for presentation at American Epilepsy Society (AES) Annual Meeting - - Agreement reached with U.S. FDA on study design and analysis approach for Phase 3 safety study of IV tramadol - - Raised $5 million in gross proceeds from public equity offering - MIAMI, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or th

GlobeNewswire 6 months ago

FBIO

FBIOP

ATXI
Avenue Therapeutics' US$4.5m Market Cap Fall Books Insider Losses

Insiders who bought US$251.0k worth of Avenue Therapeutics, Inc.'s ( NASDAQ:ATXI ) stock at an average buy price of...

Simply Wall St. 6 months ago

ATXI
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering

MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the closing of its previously announced public offering of an aggregate of 16,633,400 units (or pre-funded units in lieu thereof) at a public offering price of $0.3006 per unit (inclusive of the pre-funded warrant exercise price of $0

GlobeNewswire 6 months ago

ATXI

FBIO

FBIOP
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering

MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the pricing of its public offering of an aggregate of 16,633,400 units at a public offering price of $0.3006 per unit. Each unit consists of (i) one share of common stock (or one pre-funded warrant in lieu thereof), (ii) one Series A

GlobeNewswire 6 months ago

FBIO

FBIOP

ATXI
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer, will present a corporate update at the H.C. Wainwright 25th Annual Global Investment Conference scheduled to take place September 11-13, 2023. The presentation will be available

GlobeNewswire 8 months ago

FBIO

FBIOP

ATXI
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and Oracea® (doxycycline) with no significant safety issues Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in the second half of 2023 for DFD-29 and CUTX-101 Cosibel

GlobeNewswire 8 months ago

CKPT

FBIO

FBIOP
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

- First patient dosed in Phase 1b/2a clinical trial of AJ201; topline data anticipated in first half of 2024 - - Positive BAER-101 preclinical data demonstrate excellent anti-seizure activity in translational animal model; Phase 2a trial in epilepsy planned to initiate in 2024 - - Agreement reached with U.S. FDA on study design and analysis approach for Phase 3 safety study of IV tramadol - MIAMI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Compan

GlobeNewswire 9 months ago

ATXI

FBIO

FBIOP

Performance Overview

Return	49Y0.DU	S&P 500
YTD	-41.42%	+11.18%
1-Year	-91.22%	+29.04%
3-Year	-92.09%	+33.58%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Avenue Therapeutics Inc (49Y0.DU)

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

Avenue Therapeutics Announces Reverse Stock Split

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds

Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol

Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting

Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Avenue Therapeutics' US$4.5m Market Cap Fall Books Insider Losses

Avenue Therapeutics Announces Closing of $5.0 Million Public Offering

Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering

Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Performance Overview